Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene RET
Variant V804X
Impact List missense
Protein Effect unknown
Gene Variant Descriptions RET V804X indicates any Ret missense mutation that results in replacement of the valine (V) at amino acid 804 by a different amino acid.
Associated Drug Resistance
Category Variants Paths

RET mutant RET V804X

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_020975.6
gDNA chr10:g.43119548_43119550
cDNA c.2410_2412
Protein p.V804
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_020630 chr10:g.43119548_43119550 c.2410_2412 p.V804 RefSeq GRCh38/hg38
NM_001406743.1 chr10:g.43119548_43119550 c.2410_2412 p.V804 RefSeq GRCh38/hg38
NM_020975.5 chr10:g.43119548_43119550 c.2410_2412 p.V804 RefSeq GRCh38/hg38
NM_020975 chr10:g.43119548_43119550 c.2410_2412 p.V804 RefSeq GRCh38/hg38
NM_020630.7 chr10:g.43119548_43119550 c.2410_2412 p.V804 RefSeq GRCh38/hg38
NM_020975.6 chr10:g.43119548_43119550 c.2410_2412 p.V804 RefSeq GRCh38/hg38
NM_001406760.1 chr10:g.43119548_43119550 c.2410_2412 p.V804 RefSeq GRCh38/hg38
NM_001406744.1 chr10:g.43119548_43119550 c.2410_2412 p.V804 RefSeq GRCh38/hg38
NM_001406759.1 chr10:g.43119548_43119550 c.2410_2412 p.V804 RefSeq GRCh38/hg38
NM_020630.5 chr10:g.43119548_43119550 c.2410_2412 p.V804 RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
RET V804X medullary thyroid carcinoma not applicable N/A Guideline Risk Factor Germline RET V804X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with increased risk of developing thyroid medullary carcinoma (NCCN.org). detail...
RET V804X medullary thyroid carcinoma sensitive Pralsetinib Phase Ib/II Actionable In a Phase I/II trial (ARROW), Gavreto (pralsetinib) treatment was well-tolerated, and resulted in an overall response rate (ORR) of 65% (51/79, 5% complete response, 59% partial response) in patients with advanced or metastatic medullary thyroid cancer harboring RET mutations, 4% of the patients harbored RET V804X (Ann Oncol. Vol 31, Supplement 4, S1084, Sep 1, 2020; NCT03037385). detail...